Development of a preclinical optical frequency domain angiography instrument

临床前光频域血管造影仪的研制

基本信息

批准号：
8466296
负责人：
Benjamin James Vakoc
金额：
$ 42.62万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-05-04 至 2017-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8466296
关键词：
Algorithms Alzheimer&apos s Disease Angiography Biological Blood Blood Vessels Cancer Biology Clinical Research Complex Computer software Confocal Microscopy Data Set Development Dictionary Engineering Environment Estimation Techniques Evolution Fluorescence Frequencies General Hospitals Goals Grant Growth Height High Performance Computing Image Imaging Device Imaging technology Investigation Laboratories Lead Light Malignant Neoplasms Maps Massachusetts Measurement Methods Microscope Microscopy Modeling Nutrient Optical Coherence Tomography Optics Oxygen Pathway interactions Penetration Performance Play Preparation Process Research Research Personnel Resolution Resources Role Scanning Site Solid Neoplasm Solutions Stroke Surface System Technology Therapeutic Three-Dimensional Imaging Time Tissues Track and Field Training Translating Translations Traumatic Brain Injury Tumor Angiogenesis Tumor Volume Variant Vascular Diseases Vascular blood supply angiogenesis base exhaust improved in vivo innovation instrument instrumentation novel novel strategies optical imaging physical science pre-clinical pre-clinical research response tool tumor tumor progression

项目摘要

DESCRIPTION (provided by applicant): Tumor-induced angiogenesis plays a central role in the progression of tumors to malignancy, provides the critical transport of blood-born therapies into the tumor space, and supplies oxygen to effectuate oxygen-dependent radiological and light-based therapies. Pre-clinical research in tumor angiogenesis and tumor microvascular function has traditionally relied on histological methods, which suffer from well-known limitations, or fluorescence-based confocal and multiphoton microscopy, which provide high- resolution three-dimensional mapping of multiple parameters but support imaging over limited fields of view and depths of penetration. By contrast, optical coherence tomography approaches support a relatively larger field of view and depth of penetration and have the potential, if translated into the biological laboratory, to reveal critical and previously hidden aspects of the tumor microvasculature. In our laboratory, we have demonstrated the principles of a unique preclinical optical imaging technology that will be a powerful tool for investigating blood vessels and the biological microenvironment in vivo. The technology, optical frequency domain angiography (OFDA), supports high- resolution three-dimensional imaging similar to multiphoton and confocal microscopy. In this proposal, we propose optical, engineering, computational, and software solutions that will be required to realize a practical and robust OFDA instrument for translation into the biological laboratory. Our approach will unite investigators and resources at the Massachusetts General Hospital (MGH) and Physical Sciences, Incorporated (PSI). Innovations to the OFDA instrumentation and core algorithms will be performed by the MGH team, while construction of the computational hardware and software that is needed to improve processing will be performed by the PSI team. Our goal is to move OFDA technology from the engineering to the biological laboratory, which may catalyze research into basic cancer biology and cancer therapeutics.

描述（由申请人提供）：肿瘤诱导的血管生成在肿瘤发展到恶性肿瘤的发展中起着核心作用，提供了血出生的疗法的关键运输到肿瘤空间中，并提供氧气以实现依赖氧依赖性的放射线和光基疗法。传统上，肿瘤血管生成和肿瘤微血管功能的临床前研究依赖于组织学方法，这些方法受到了众所周知的局限性或基于荧光的共聚焦和多光子显微镜，这些方法提供了高分辨率的多个参数的三维映射，但在有限的视图和渗透率的范围内进行了成像。相比之下，光学相干断层扫描方法支持相对较大的视野和渗透深度，如果将其转换为生物实验室，则具有揭示肿瘤微脉管系统的关键和以前隐藏的方面的潜力。在我们的实验室中，我们展示了独特的临床前光学成像技术的原理，该技术将成为研究血管和体内生物微环境的强大工具。该技术是光频域血管造影（OFDA），支持高分辨率的三维成像，类似于多光子和共聚焦显微镜。在此提案中，我们提出了光学，工程，计算和软件解决方案，这些解决方案将被要求实现一种实用且强大的OFDA仪器，以转化为生物实验室。我们的方法将在马萨诸塞州总医院（MGH）和Incorporated（PSI）的物理科学和物理科学公司团结研究人员和资源。 MGH团队将对OFDA仪器和核心算法进行创新，而PSI团队将执行改进处理所需的计算硬件和软件的构建。我们的目标是将OFDA技术从工程转移到生物实验室，这可能会促进基本癌症生物学和癌症治疗剂的研究。